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RNA polymerase III (RNA pol III) transcribes many of the small structural RNA molecules involved in process-
ing and translation, thereby regulating the growth rate of a cell. Initiation of pol III transcription requires the 
evolutionarily conserved pol III initiation factor TFIIIB. TFIIIB is the molecular target of regulation by tumor 
suppressors, including p53, RB and the RB-related pocket proteins. However, our understanding of negative 
regulation of human TFIIIB-mediated transcription by other proteins is limited. In this study we characterize a 
RNA pol III luciferase assay and further demonstrate in vivo that a human homolog of yeast Maf1 represses RNA 
pol III transcription. Additionally, we show that Maf1 repression of RNA pol III transcription occurs via TFIIIB, 
specifically through the TFIIB family members Brf1 and Brf2.  
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1.  Introduction 
Eukaryotic cells divide the responsibility of tran-
scribing cellular genes among three DNA dependent 
RNA polymerases [1]. RNA pol I transcribes rRNA, 
RNA pol II transcribes mRNA, as well as a few of the 
small nuclear RNAs (snRNAs) involved in splicing, 
and RNA pol III transcribes the small structural RNAs 
involved in processing and translation [2]. RNA pol III 
is the largest of the eukaryotic polymerases and has the 
greatest number of subunits, yet its transcriptional 
products are untranslated RNAs that are usually 
smaller than 300 nucleotides in length [2, 3]. The genes 
transcribed by human RNA pol III may be further 
subdivided according to promoter structure, which 
may be entirely gene internal (type 1 and 2) or external 
(type 3), and basal transcription factor requirements [4]. 
Recruitment of RNA pol III is a consequence of specific 
transcription factor complex assembly on the different 
classes of promoters [2]. Ultimately, proper initiation 
by RNA pol III requires TFIIIB [2, 5-8]. 
S. cerevisiae TFIIIB is well defined, comprised of 
three polypeptides, the TATA box binding protein TBP, 
the TFIIB related factor Brf1, and a third polypeptide 
Bdp1[7-9]. All three polypeptides are necessary and 
sufficient to reconstitute TFIIIB activity in yeast [6, 10, 
11]. In humans, TFIIIB activity is more complex, as at 
least two forms of TFIIIB activity have been identified 
[12-15]. Transcription from gene internal promoters, 
such as tRNA genes, requires a TFIIIB complex com-
prised of TBP, Brf1 and Bdp1, whereas expression 
from gene external promoters, such as the U6 snRNA 
gene, require a TFIIIB complex containing TBP, Brf2 
and Bdp1 [2, 13, 14].   
  RNA pol III activity is intimately linked to 
growth conditions and is tightly regulated throughout 
the cell cycle; RNA pol III activity is low during mitosis, 
increases slowly through G1 and reaches its maximal 
activity during the S and G2 phases [16, 17]. As such, 
RNA pol III transcription is a target of regulation by 
tumor suppressors including p53, RB, and the 
RB-related pocket proteins [18-20]. Specifically, the 
tumor suppressors p53, RB, p130, and p107 have been 
demonstrated to inactivate RNA pol III transcription 
through physical associations with TFIIIB subunits at 
different stages of the cell cycle [19, 21, 22].  
Maf1 has been identified as a global repressor of 
pol III transcription in yeast [5, 23-25], see [26, 27] for a 
review. The repressing activity of Maf1 was originally 
proposed based, in part, on the observation that maf1 
mutant yeast cells have higher levels of mature tRNAs, 
as compared to wild-type [28]. Subsequently, yeast 
Maf1 was shown to be required for down-regulation of 
RNA pol III transcription during the growth cycle and 
in response to nutrient limitation, DNA damage, oxi-
dative stress and a variety of drug treatments [5, 24]. 
Hence, conditions that cause inhibition of cell prolif-
eration, at least in yeast, appear to activate different 
signaling pathways that converge on Maf1 and regu-
late its repressing activity [24, 25]. It has been deter-
mined that two important targets of yeast Maf1 re-
pression are the TFIIIB subunit Brf1 and RNA pol III [5, 
24]. Yeast Maf1 co-precipitates with Pol III and Brf1 [5, 
24] and recombinant Maf1 has been shown to inhibit Int. J. Biol. Sci. 2007, 3 
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tRNA transcription in vitro [5]. Recently, it has been 
demonstrated that phosphorylation and dephos-
phorylation of Maf1 by protein kinase A and protein 
phosphatase 2A respectively, regulate the cellular lo-
calization of Maf1 and hence its ability to repress 
transcription [24, 29-31]. Putative Maf1 homologs have 
been identified in a variety of organisms, including 
humans, and it has been speculated that the function of 
Maf1 will be conserved from yeast to man [28]. The 
Maf1 orthologs are highly conserved; containing three 
regions (termed A, B, C) with a high degree of se-
quence similarity, but with unknown function [28]. 
Only recently has a role for human Maf1 in RNA pol 
III transcription been described, whereby Reina et al. 
[32] demonstrate that human Maf1 represses RNA pol 
III transcription from type 1, 2, and 3 promoters in vitro 
and that endogenous Maf1 associates with Brf1 and the 
largest subunit of RNA pol III via 
co-immunoprecipitation and pull-down assays.  
In contrast to yeast, there are at least two forms of 
human TFIIIB, each requiring different TFIIB family 
members for transcription from the different classes of 
RNA pol III promoters [2, 13, 14]. Thus, we sought to 
determine if a putative human homolog of yeast Maf1 
functions as an in vivo repressor of gene internal RNA 
pol III transcription through the TFIIB family member 
Brf1, and whether human Maf1 would be able to also 
repress gene external RNA pol III transcription 
through the TFIIB family member Brf2, which does not 
have a functional homolog in yeast.  
Here we report that a human homolog of yeast 
Maf1 represses RNA pol III transcription from both 
gene -internal and -external promoters through TFIIIB 
using an in vivo RNA pol III luciferase assay. We fur-
ther demonstrate that human Maf1 is capable of re-
pressing two forms of human TFIIIB activity via the 
TFIIB family members Brf1 and Brf2. Specifically, we 
have identified a mechanism by which Maf1 inhibits 
U6 transcription through direct interactions with Brf2. 
2.  Materials and Methods 
Luciferase reporter constructs 
The human U6 promoter was cloned by PCR 
from human genomic DNA (Clontech) using primers 
previously described [33] with the restriction sites for 
Kpn I and Bgl II added to the forward and reverse 
primers, respectively, allowing directional cloning into 
the pGL3 basic luciferase vector, which lacks eu-
karyotic promoter and enhancer sequences (Promega). 
The VAI promoter region was amplified by PCR from 
the pADVantage vector (nucleotides 780-939) 
(Promega) and subsequently directionally cloned into 
pGL3 using the Kpn I and Bgl II restriction sites. A 
mutant U6 construct, (pGL3-mtU6) containing muta-
tions in the proximal sequence element (PSE) and the 
TATA box was generated by PCR, using a plasmid 
with a mutant human PSE and TATA box as a tem-
plate, which has been described [34-36]. A deletion 
pGL3-VAI construct for the VAI promoter was gener-
ated as previously described [37]. pGL3mtTATAU6 
was generated using previously characterized muta-
tions in the TATA box of pGL3-U6 [38]. A mutant 
pGL3-U6TTT was generated by PCR to add a previ-
ously characterized tandem run of 6T residues 
(5’-AGCTTTTTTGGAATTTTTTGGAAAGCCAC-3’) 
[39] downstream of the U6 promoter, but upstream of 
the Kozak consensus translation initiation site of the 
luciferase coding sequence of pGL3. 
Mammalian expression constructs 
3XFlagMaf1 was generated by PCR amplification 
of the coding sequence of Maf1 (Genbank accession 
number NM032272) from HeLa cDNA and ligated into 
the Xba I and BamH I sites of p3XFlag-CMV7.1 (Sigma). 
Mammalian expression vectors for Brf1 and Brf2 were 
generated by PCR amplification of coding sequences of 
pSBETFlag/HTBrf1[13]and  pSBETFlag/HT-Brf2 and 
ligated into the Xba I and BamH I sites of 
p3XFlag-CMV-7.1 (Sigma). GFP-Brf2 was generated by 
PCR amplification of Brf2 coding sequence and sub-
sequent ligation into the Kpn I and BamH I sites of 
pEGFP-N3 (BD Biosciences Clontech). For GSTMaf1 
used in vitro GST pull-down assay, we PCR amplified 
Maf1 sequence from HeLa cDNA and ligated the cod-
ing sequence in frame of GST tag using the BamH I 
and EcoR I sites of pGEX-5X-1(Pharmacia Biotech) and 
expressed and purified as previously described [13]. 
Cell culture and luciferase assays 
HeLa cells (ATCC) were maintained in 10% FBS 
DMEM (Biowhittaker). Transient transfections were 
accomplished using TransIT-LT1 (Mirus), as per the 
manufacturer’s protocol. Dual-luciferase reporter as-
say system (Promega) was used to monitor luciferase 
activity in HeLa cells as per the manufacturer’s rec-
ommendations, using a Sirius single tube luminometer 
(Berthold). A Renilla luciferase vector (Promega) was 
co-transfected in all transfections described to monitor 
transfection efficiency. Luciferase experiments were 
performed in triplicate or quadruplicate, repeated 
three independent times, and the data presented are 
representative experiments. All luciferase results are 
reported as relative light units (RLU): the average of 
the Photinus pyralis firefly activity observed divided by 
the average of the activity recorded from Renilla 
luciferase vector.  Results were analyzed using 
Graphpad PRISM 3.03. 
Immunofluorescence 
Transiently transfected HeLa cells were fixed in 
either 4% paraformaldehyde for 20 minutes or 0.5% 
paraformaldehyde overnight. Cells were permeabi-
lized with 0.2%Triton-X for 20 minutes, blocked in 10% 
goat serum for 45 minutes at room temperature or 
overnight at 4oC. All 1o antibodies, rabbit and mouse 
anti-Flag (Sigma) and rabbit anti-GFP (Molecular 
Probes), were diluted 1:100 in 2% goat serum and cells 
were incubated for 1 hour. FITC-conjugated goat anti 
rabbit IgG (Amersham Biosciences) and Alexa-546 
conjugated goat anti mouse IgG (Molecular Probes) 
secondary antibodies were diluted 1:200 with 2% goat 
serum. Cells that were stained with propidium iodide 
(5ug/ml) were incubated for 5 min. after pretreatment Int. J. Biol. Sci. 2007, 3 
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with RNase (Roche) or stained with DAPI (Sigma) to 
determine nuclear localization. All images were cap-
tured using a laser scanning confocal microscope 
(Leica TCS SL) 
Co-immunoprecipitation and GST pull-down as-
says 
Nuclear extract was prepared from HeLa cells [13] 
transfected with FlagMaf1 or empty Flag vectors and 
incubated with NET-2 (150 mM NaCl/40 mM 
Tris•HCl, pH 7.5/0.05% TritonX-100) equilibrated 
Flag M2 agarose (Sigma) overnight at 4 degrees, then 
extensively washed with NET-2 and eluted with Flag 
peptide (Sigma). Eluants were resolved by SDS-PAGE, 
wet transferred to nitrocellulose and subsequently 
immuno-blotted with anti-Brf2 antibody (CSH 1228), a 
generous gift from N. Hernandez, Cold Spring Harbor 
Laboratory. Flag/HTBrf2, GSTMaf1 and the empty 
GST vector were expressed and purified as previously 
described [13, 40] and mixed with TBS (100 mM 
Tris-HCl, 0.9% NaCl, pH 7.4) equilibrated GST agarose 
(Sigma) overnight at 4 degrees, then extensively 
washed with TBS, containing 300mM NaCl, and eluted 
in 50mM Tris containing 10mM reduced glutathione. 
Eluants were resolved by SDS-PAGE, wet transferred 
to nitrocellulose and subsequently immunoblotted 
with anti-Flag antibody (Sigma). 
Western blot analysis 
Transiently transfected cells were harvested and 
nuclear extract was prepared as previously described 
[13]. Nuclear extract was separated on 10% SDS-PAGE 
gels, wet transferred to nitrocellulose, blocked 1 hour 
room temperature using nonfat milk in Tris Buffered 
Saline (TBS), pH 7.5. The blot(s) were incubated in 
primary antibodies: anti-actin (Santa Cruz), anti-Flag 
polyclonal (Sigma), overnight at 4 degrees. The blot(s) 
were washed in 1X TBS and then incubated in secon-
dary antibody at room temperature, then developed 
using ECF (for anti-rabbit-AP or anti-mouse-AP anti-
bodies, Amersham) or TMB substrate (Promega) (for 
anti-goat-HRP, Amersham) and photodocumented 
using a BioDocit system (UVP).  
3.  Results 
Transcription from gene internal (VAI) and gene 
external (U6) promoters can be monitored in HeLa 
cells using a dual luciferase assay.  
RNA pol III transcribes both gene- internal and 
external promoters as exemplified by the VAI (a pro-
totypical tRNA-like promoter) and human U6 pro-
moters, respectively. Previously, most of our under-
standing of the mechanisms of RNA pol III transcrip-
tion has come from in vitro transcription assays utiliz-
ing nuclear or whole cell extracts prepared from 
mammalian cells grown in culture. Although this 
methodology has been invaluable for understanding 
RNA polymerase III transcription and in the subse-
quent identification of transcription factors, the major 
limitation is our inability to investigate the regulation 
of RNA pol III transcription in intact mammalian cells. 
Therefore, we sought to develop and characterize a 
reporter assay that could be used to study RNA pol III 
transcription from gene –internal and –external pro-
moters in intact mammalian cells.  
To determine if we could monitor gene external 
RNA pol III promoter activity in vivo we PCR ampli-
fied the human U6 promoter from human genomic 
DNA as previously described [33]. This human U6 
promoter contains both a proximal sequence element 
(PSE) and TATA box located upstream of the tran-
scription start site and was ligated into pGL3-basic, 
lacking both promoter and enhancer sequences, re-
sulting in pGL3-U6. pGL3-U6 was transiently trans-
fected into HeLa cells yielding higher luciferase activ-
ity, as compared to the empty pGL3 vector (Figure 1A). 
Addition of increasing amounts of pGL3-U6 resulted 
in a dose-dependent increase in luciferase activity. 
These results are in agreement with a recent report 
demonstrating that both the human and mouse U6 
promoters can drive luciferase expression in a pro-
moterless pGL4.10 plasmid [39]. To examine whether 
expression of the luciferase reporter in HeLa cells 
could be driven by a gene internal RNA polymerase III 
promoter in vivo, we utilized the well studied VAI gene, 
a prototypical tRNA-like promoter. The VAI gene has 
canonical A and B box promoter elements located 
downstream of the transcription start site. The VAI 
gene was PCR amplified from pADVantage and 
ligated into pGL3-Basic, yielding pGL3-VAI which 
was transiently transfected into HeLa cells and dem-
onstrated a dose response increase in luciferase activ-
ity, as compared to the empty pGL3 vector (Figure 1A). 
Taken together these data suggest that gene-internal 
and -external RNA pol III promoter activity may be 
monitored in HeLa cells using this luciferase assay.  
Previously, the issue has been raised as to 
whether RNA pol II can transcribe RNA pol III pro-
moters in short hairpin RNA (shRNA) expression 
vectors [39]. Hence, we sought to determine if the ob-
served luciferase activities from luciferase vectors 
driven by RNA pol III promoters (Figures 1A) were 
specific to RNA pol III transcription. We generated a 
mutant pGL3-U6 expression construct (pGL3-mtU6) 
with previously characterized mutations in both the 
PSE and TATA box [35, 36] and tested its ability to 
express luciferase in transiently transfected HeLa cells. 
As depicted in Figure 1B, mutations in the PSE and 
TATA box of the human U6 promoter abolishes 
l u c i f e r a s e  a c t i v i t y  i n  H e L a  c e l l s ,  a s  c o m p a r e d  t o  
luciferase activity driven by the wild type human U6 
promoter. We also determined the specificity of pol III 
transcription from the human pGL3-VAI construct by 
generating a previously characterized deletion mutant 
[37] lacking both the canonical A and B box promoter 
elements of VAI. This construct was subsequently 
tested in our luciferase assay, and as expected, deletion 
of the A and B boxes severely inhibited VAI transcrip-
tion (Figure 1C).  
To ensure that our RNA pol III luciferase assay 
was indeed measuring RNA pol III and not cryptic 
RNA pol II activity, we tested whether this RNA pol III Int. J. Biol. Sci. 2007, 3 
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luciferase assay followed the classical alpha-amanitin 
sensitivity profile established for eukaryotic DNA de-
pendent RNA polymerases [41]. We observed that 
pGL3-U6 luciferase activity was not affected at low 
doses of alpha amanitin (3ug/ml), but transcription 
from a RNA pol II-like promoter 
[38](pGL3-mtTATAU6) was decreased at 3 ug/ml 
(Figure 1D). Also, transcription from pGL3-VAI was 
not inhibited at 2 ug/ml alpha amanitin, whereas 
transcription from pGL3-mtTATAU6 was severely 
inhibited 2 ug/ml alpha amanitin (Figure 1E).  
 To determine if we could artificially terminate 
RNA pol III transcription in our system, we inserted a 
prototypical RNA pol III termination sequence, a tan-
dem oligo containing 6T residues downstream of the 
human U6 promoter, but upstream of the Kozak con-
sensus translation initiation site of the luciferase cod-
ing sequence of pGL3 [39, 42]. The insertion of a run of 
six T residues severely inhibited luciferase activity 
from the pGL3-U6 promoter (Figure 1F), as compared 
to wild-type pGL3-U6. These results differ from Rumi 
et al [39] who were unable to demonstrate that the 
insertion of a RNA pol III termination signal down-
stream of the human U6 promoter and upstream of the 
luciferase start ATG significantly inhibited RNA pol III 
transcription. A potentially important difference is 
vector construction. Rumi et al inserted the EGFP 
shRNA sequence between the human H1 promoter 
and the RNA pol III terminator sequence [39]. Using 
TESS: Transcription Element Search Software [43], we 
determined that the EGFP shRNA sequence contains 
putative RNA pol II transcription factor binding sites 
which may serve to enhance cryptic RNA pol II tran-
scription from the human H1 promoter in the pGL4.10 
utilized by Rumi et al [39]. 
 Int. J. Biol. Sci. 2007, 3 
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Figure 1. RNA polymerase III transcription can be 
measured in vivo using a RNA pol III dual luciferase 
assay. (A) Transient transfection of HeLa cells with in-
creasing concentrations of pGL3-U6 (100ng, 200ng, 
300ng), pGL3-VAI (100ng, 200ng, 300ng) or empty pGL3 
vector (300ng). (B) Luciferase activity comparison of the 
wild-type human U6 promoter (100ng) with a mutant 
human U6 promoter, lacking a functional TATA box and 
PSE (100ng). Cells were also transfected with empty 
pGL3 (100ng) as negative control. (C) Comparison of 
wild-type VAI (100ng) promoter luciferase activity with a 
mutant VAI construct lacking both the A and B box pro-
moter elements of the VAI promoter (100ng). Cells were 
also transfected with empty pGL3 (100ng) as negative 
control. (D) HeLa cells transiently transfected with either 
empty pGL3 (50ng), wild-type pGL3-U6 (50ng), or a 
previously characterized mutant U6 lacking a functional 
TATA box and transcribed by RNA pol II, 
pGL3-mtTATAU6 (25ng) and treated with 0 μg/ml or 3 
μg/ml α-amanitin. (E) HeLa cells transiently transfected 
with either empty pGL3 (100ng), wild-type pGL3-VAI 
(100ng), or a previously characterized mutant U6 lacking a 
functional TATA box and transcribed by RNA pol II, 
pGL3-mtTATAU6 (50ng) and treated with 0 μg/ml, 1 
μg/ml or 2 μg/ml α-amanitin. (F) Transient transfection of 
pGL3 (100ng), pGL3-U6 (100ng), or pGL3-U6TTT 
(100ng) with a run of T residues inserted downstream of 
the human U6 promoter, but upstream of the the Kozak 
consensus translation initiation site of the luciferase gene 
in pGL3. All luciferase assay results expressed as relative 
light units (RLU): the average of the Photinus pyralis 
firefly activity observed divided by the average of the 
activity recorded from Renilla luciferase vector. Experi-
ments were done in triplicate, repeated three times, rep-
resentative experiments are depicted. 
 
Taken together (Figures 1A-1F) these data sug-
gest that our RNA pol III luciferase assay can specifi-
cally and effectively monitor transcription from pro-
totypical gene- internal and -external RNA pol III 
promoters. 
Human Maf1 represses RNA pol III transcription 
in HeLa cells 
To determine if the putative human homolog of 
yeast Maf1 is indeed a repressor of human RNA pol III 
transcription, we sub-cloned human Maf1 (Genbank 
accession number NM032272) from HeLa cDNA into 
p3XFlag-CMV-7.1 and transiently co-transfected the 
construct with pGL3-U6 into HeLa cells. By western 
blot (Figure 2A), the 3XFlag-tagged Maf1 construct 
expresses at detectable levels in HeLa cells, as com-
pared to HeLa cells transfected with the empty Flag 
vector. Interestingly, we routinely observed a doublet, 
indicated by asterisks, when expressing Flag-Maf1 in 
HeLa cells (lane 2 Figure 2A). We speculate that the 
observed upper band is a phosphorylated form of 
Maf1, consistent with the properties of Maf1 in yeast 
[29, 30] and a recent report regarding mammalian 
Maf1[32]. To determine if Maf1 is indeed phosphory-
lated, we treated the FlagMaf1 expressing HeLa nu-
clear extract with calf intestine phosphatase for various 
times and analyzed the samples by anti-Flag western 
blot. We demonstrated a loss in the upper band and a 
proportional increase in the lower faster migrating 
band (Figure 2C). As of yet, it is unclear if this ob-
served dephosphorylation of human Maf1 plays the 
same important role in the regulation of RNA pol III 
transcription recently observed in yeast [30, 31].  
To determine if human Maf1 is a repressor of 
RNA pol III transcription, like its yeast counterpart, we 
performed transient transfections and demonstrated 
that increasing concentrations of Maf1 inhibited both 
U6- and VAI-driven luciferase activity in a dose- de-
pendent manner (Figure 2D). Taken together these 
luciferase data suggest that human Maf1 is an inhibitor 
of both gene internal and gene external RNA pol III 
transcription in vivo and these data are in agreement 
with a recent report demonstrating Maf1 regulation of 
human RNA pol III transcription using nuclear run on 
(VAI) and RNA protection (U6) assays in vitro [32]. Int. J. Biol. Sci. 2007, 3 
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Figure 2. Human Maf1 inhibits RNA polymerase III transcription from both gene internal and gene external pro-
moters. (A) Anti-flag immunoblot of nuclear extract prepared from HeLa cells transiently transfected with: empty flag vector 
(lane 1), FlagMaf1 (lane 2), FlagBrf1 (lane 3), FlagBrf2 (lane 4). Arrows depict location of each protein as determined by 
anti-Flag antibody. Asterisks denote polypeptide doublet routinely observed in HeLa cells over-expressing FlagMaf1. (B) 
Same immunoblot from 2A reprobed using anti-actin antibody as loading control for transfections with FlagBrf1, FlagBrf2 
and empty Flag vector. (C) Nuclear extract prepared from HeLa cells over-expressing FlagMaf1 treated with calf intestine 
phosphatase (CIP) for increasing amounts of time and immunoblotted with an anti-Flag antibody. (D) Transient transfection 
of HeLa cells with pGL3-VAI (100ng) (left panel) or pGL3-U6 (100ng) (right panel) with increasing amounts of Flag-
Maf1(50ng, 100ng, 200ng) and empty vectors Flag (200ng) and pGL3(100ng) as indicated by + sign. 
 
Repression of RNA Pol III transcription by Maf1 
occurs through the TFIIB family members Brf1 and 
Brf2 
Desai et al [5] identified a two step mechanism by 
which yeast Maf1 represses RNA pol III transcription: 
(1) inhibition of TFIIIB assembly at the promoter and (2) 
inhibition of RNA pol III recruitment to TFIIIB already 
assembled on promoters under conditions which favor 
cellular growth repression. To elucidate whether hu-
man Maf1 represses RNA pol III transcription by a 
similar mechanism, we attempted to overexpress the 
TFIIIB subunits Brf1 and Brf2 to determine if this 
would alleviate repression of RNA pol III transcription 
by human Maf1. Overexpression of human Brf1 in 
HeLa cells co-expressing human Maf1 alleviates the 
observed repression of RNA pol III transcription from 
the VAI promoter (Figure 3A). We are able to restore 
RNA pol III activity in the Maf1 repressed HeLa cells 
to activity levels similar to that observed in the control 
HeLa cells by the overexpression of Brf1 (Figure 3A). 
These results suggest that inhibition of VAI transcrip-Int. J. Biol. Sci. 2007, 3 
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tion by human Maf1 occurs via the TFIIIB subunit Brf1, 
suggesting a similar mechanism to that observed in 
yeast [5, 24]. Furthermore, Reina et al [32] demon-
strated Maf1 physically associates with Brf1 and the 
RNA pol III subunit RPC1 by co-immunoprecipitation 
assays. 
Yeast cells do not utilize gene-external RNA pol 
III promoters of the type that require Brf2 for tran-
scription in human cells [2, 13]. Thus, it is not known 
whether Brf2, like Brf1, is a molecular target of Maf1 
repression. To address this question, we tested 
whether transient overexpression of Brf2 can rescue U6 
promoter-driven luciferase activity in HeLa cells 
co-transfected with Maf1. Co-transfection of human 
Brf2 with Maf1 could only restore activity to ap-
proximately 50% of the control luciferase activity ob-
served in the control HeLa cells not transfected with 
the Maf1 construct (Figure 3B). Although we were able 
to alleviate Maf1 repression of U6 transcription nearly 
50%, by the co-expression of GFP-Brf2, we were never 
able to restore U6 transcription levels to those seen in 
the control HeLa cells transfected with the U6 pro-
moter and the vector expressing only the Flag epitope. 
Currently, we cannot rule out the possibility that 
overexpression of a GFP-Brf2 fusion is not as efficient 
at rescuing Maf1 repression. Alternatively or in addi-
tion, the U6 promoter may be more sensitive than the 
VA1 promoter to other effects of Maf1-dependent re-
pression. To further investigate the mechanism by 
which Maf1 represses U6 transcription we sought to 
determine if Brf2 and Maf1 could co-localize in HeLa 
cells.  
 
Figure 3. Overexpression of the TFIIIB subunits Brf1 or Brf2 alleviates Maf1 induced repression of transcription 
from both gene internal and external promoters RNA polymerase III. (A) HeLa cells were transiently transfected with: 
pGL3 and Flag vector, or pGL3-VAI and Flag vector, pGL3-VAI and FlagMaf1, pGL3-VAI, FlagMaf1 and Brf1. (B) HeLa 
cells were transiently transfected with: pGL3 and Flag vector, or pGL3-U6 and Flag vector, pGL3-U6 and FlagMaf1, 
pGL3-U6, FlagMaf1 and Brf2. 
 
Human Maf1 interacts with Brf2 in HeLa cells 
To date there have been few reports depicting the 
dynamics of TFIIIB by immunofluorescence in living 
mammalian cells [44, 45]. Recently, Chen et al investi-
gated the physical association of the TFIIIB subunit 
TBP with chromosomes during the cell cycle, and de-
termined that TBP stably associates with the con-
densed mitotic chromosomes, despite the known inac-
tivation of TFIIIB and the inhibition of RNA pol III 
transcription that occurs during mitosis [44].  
 There is little experimental evidence depicting 
the physical localization of human TFIIIB and known 
repressors of RNA pol III transcription. Hence, we 
sought to determine if our epitope tagged TFIIIB sub-
unit Brf2 and the RNA pol III repressor Maf1 con-
structs were able to localize to the nucleus. FlagBrf2 
was transiently transfected into HeLa cells and local-
i z e d  t o  t h e  n u c l e u s ,  a s  j u d g e d  b y  p r o p i d i u m  i o d i d e 
staining (Figure 4A). In contrast to the localization 
patterns of FlagMaf1 and FlagBrf2, the vector ex-
pressing only the Flag epitope showed primarily cy-
toplasmic staining with little or no signal in the nu-
cleus (Figure 4A). In Figure 4B, FlagMaf1 and 
GFP-Brf2 were co-transfected into HeLa cells where 
they co-localized. Both the Brf2 and Maf1 constructs 
localized to the nucleus as judged by DAPI staining 
(data not shown).  Int. J. Biol. Sci. 2007, 3 
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Figure 4. Human Maf1 and Brf2 co-localize in HeLa cells. (A) HeLa cells transfected with empty Flag vector (left upper 
panel), FlagBrf2 (center left panel), or FlagMaf1 (lower left panel) and localization of proteins determined using an anti-Flag 
antibody denoted in green. Propidium iodide (PI), center left panels, identify the nucleus of HeLa cells. Overlay of cells 
stained with anti-Flag and PI demonstrate the nuclear localization of FlagMaf1 and FlagBrf2, right center panels. Right panels 
show the DIC and overlay of the transfected HeLa cells. (B) HeLa cells transfected with either empty Flag and GFP vectors or 
FlagMaf1 and Brf2GFP. Right panels demonstrate location of GFP signal (green), left center panels the Flag signal (red), 
overlay shows co-localization of FlagMaf1 and Brf2-GFP (yellow). 
 
To further elucidate whether Maf1 physically 
associates with Brf2 we performed 
co-immunoprecipitation (co-IP) experiments. HeLa 
cells were transiently transfected with either the empty 
Flag vector or FlagMaf1 and nuclear extract was pre-
pared. After incubation with M2 Flag agarose, the 
immunoprecipitates (IP) were extensively washed and 
the precipitated complexes were eluted using Flag Int. J. Biol. Sci. 2007, 3 
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peptide. The complexes were separated by SDS-PAGE 
and we immunoblotted using an anti-Brf2 antibody 
(CSH 1228), as previously described [13]. We find that 
FlagMaf1 specifically interacts with endogenous Brf2, 
( F i g u r e  5 A ,  l a n e  6 ) ,  a s  n o  B r f 2  w a s  d e t e c t e d  i n  t h e  
anti-Flag alone IP (Figure 5A, lane 5). This suggests 
that human Maf1 interacts with the TFIIIB subunit Brf2, 
but these experiments do not provide insight whether 
this is a direct or indirect interaction. To discriminate 
between these two possibilities we expressed and pu-
rified recombinant Flag/HTBrf2 and GSTMaf1 in E. 
coli, as previously described [13]. Using a GST 
pull-down assay, we demonstrate that Maf1 interacts 
directly with the TFIIIB subunit Brf2 (Figure 5B, lane 2). 
Taken together co-localization, co-immuno-
precipitation, and GST pulldown assays strongly sug-
gest that human Maf1 exerts its ability to inhibit RNA 
pol III U6 transcription through direct interaction with 
the TFIIIB subunit Brf2.  
 
Figure 5. Maf1 directly associates with the TFIIB family member Brf2. (A) Nuclear extracts from HeLa cells transiently 
transfected with the empty Flag vector or FlagMaf1 were mixed with Flag agarose, subsequently immunoblotted with the 
gene specific anti-Brf2 antibody CSH 1228. Nuclear extract inputs: untransfected nuclear extract (lane 1) empty Flag vector 
(lane 2), and FlagMaf1 (lane 3). Immunoprecipitates: Flag vector (lane 5), and FlagMaf1 (lane 6). Arrow denotes migration 
location of endogenous Brf2 protein. (B) Recombinant Flag/HTBrf2 and GSTMaf1 were mixed with anti-glutathione agarose 
and immunoprecipitates were immunoblotted with an anti-Flag antibody. Increasing amounts of recombinant Flag/HTBrf2 
(lanes 6 and 7), recombinant GST (lane 5), and recombinant GSTMaf1 (lane 4), immune complexes from anti-GST (lane 3) 
and anti-GSTMaf1 (lane 2) immunoprecipitations. Arrow denotes location of Flag/HT Brf2, as determined by anti-Flag an-
tibody. 
 
4.  Discussion 
In this study we have constructed RNA pol III 
type 2 and 3 promoter fusions to the Photinus pyralis 
luciferase gene that enable RNA polymerase III tran-
scription to be monitored in vivo. We demonstrate 
specific monitoring of transcriptional activity from 
both gene internal and gene external RNA pol III 
promoters (Figures 1A through 1F). Although the use 
of the luciferase gene fused to prototypical RNA pol III 
promoters to monitor both type 2 and type 3 RNA pol 
III transciption in vivo is novel, the ability of RNA pol 
III to generate functional mRNAs has been docu-
mented in other studies [46]. It has been demonstrated 
that the human VAI promoter can drive expression of 
the Tat gene in vivo and that this VA-Tat RNA synthe-
sized by RNA pol III is scanned for translational ini-
tiation, despite being uncapped [46, 47]. Examination 
of the luciferase coding sequence in pGL3 Basic reveals 
several regions with a run of four or more T residues 
which could potentially be used as termination signals 
by RNA pol III. However, it has been demonstrated 
that some RNA pol III transcripts such as rabbit 
tRNAlys, Xenopus laevis tRNAlys and the yeast tRNAser 
transcripts contain internal stretches of T residues in-
dicating that a cluster of T residues are not always 
sufficient for efficient termination by RNA pol III [48]. 
This was clearly demonstrated in Xenopus laevis 5S 
RNA which requires a G + C rich sequence, sur-
rounding a cluster of T residues for efficient termina-Int. J. Biol. Sci. 2007, 3 
 
301
tion by RNA pol III [49]. To ascertain if we were indeed 
measuring RNA pol III transcription we inserted a 
putative termination signal for RNA pol III, a run T 
residues downstream of the U6 promoter, but up-
stream of the start ATG of the luciferase gene of 
pGL3-U6, which inhibited luciferase expression (Fig-
ure 1F).   
We also provide experimental evidence that a 
human homolog of yeast Maf1 is a repressor of type 2 
and 3 RNA pol III transcription (Figure 2D) using an in 
vivo luciferase assay. These results are in agreement 
with Reina et al’s [32] report that, human Maf1 inhibits 
RNA pol III transcription from both gene internal and 
gene external promoters using in vitro nuclear run on 
and RNA protection assays. We have confirmed that 
over expression of the TFIIB family members Brf1 and 
Brf2 alleviate Maf1 repression from gene internal and 
gene external RNA pol III promoters, respectively, 
suggesting that human Maf1 exerts its repressional 
activity, at least in part, through the TFIIIB complex 
(Figure 3). We have further identified a mechanism by 
which Maf1 represses U6 transcription by identifying a 
physical association, using co-localization, 
co-immunoprecipitation and GST pull-down assays, 
with the TFIIIB subunit Brf2 (Figure 5). Interestingly, 
Reina et al [32] were not able to detect a physical asso-
ciation between Maf1 and Brf2, using in vitro tran-
scribed/translated Brf2 and there was no mention if 
the authors had attempted to detect a Maf1 and Brf2 
association using the co-immunoprecipitation assay 
utilized to discern the Brf1 and RPC1 interaction with 
Maf1.  
Although a role for Maf1 repressing human RNA 
pol III transcription in vitro has been recently demon-
strated [32], our work presents further insight into the 
mechanism of repression in vivo. We show that inter-
actions with the TFIIIB components Brf1 and Brf2 also 
play a role. Potentially, the interaction of Maf1 with 
Brf2 may be weaker than that with Brf1.  
It is currently unclear whether phosphorylation 
and dephosphorylation of human Maf1 plays a critical 
role in the regulation of RNA pol III in a manner simi-
lar to that observed in yeast [24, 29-31]. We also pro-
vide in this report evidence that human Maf1 is a 
phosphoprotein (Figure 2C). It has yet to be discerned 
if the human homologs of the PP2A, PKA and Pkc1 
will play similar roles in regulating human Maf1 
[29-31]. Using the NetPhos prediction software [50], 
we have identified putative phosphorylation sites in 
Maf1 for PKC, PKA, Akt, Clk2, CK1, CK2, GSK3, 
CDC2, and Erk1, potentially placing Maf1 in a wide 
variety of signal transduction pathways, allowing 
Maf1 to transduce signals and thereby regulating RNA 
pol III transcription under a variety of growth condi-
tions. As there are at least two forms of human TFIIIB, 
each requiring a different TFIIB family member for 
initiation from gene internal (Brf1) and gene external 
(Brf2) promoters; it is plausible that these different 
kinase(s) and phosphatase(s) may exert differential 
effects on these different TFIIB family members.  
The generation of the in vivo FlagMaf1 construct 
and the characterization of an in vivo RNA pol III 
luciferase assay will be invaluable tools to help eluci-
date the signal transduction pathways Maf1 interacts 
with to exert its regulation on RNA pol III transcrip-
tion.  
Finally, the characterization of an in vivo RNA 
polymerase III luciferase assay provides an advantage 
to study the mechanisms of both gene –internal and 
–external RNA pol III transcription in intact mammal-
ian cells. This assay will allow us to monitor RNA pol 
III activity under a variety of conditions, including: 
DNA damage, oxidative stress, mitogenic stimulus, 
and environmental toxins. This methodology will be-
come an invaluable tool to rapidly screen compounds 
for their ability to inhibit or stimulate RNA pol III 
transcription. Thus, this RNA pol III luciferase assay 
could be used as a high through put screening method 
to identify and characterize pharmacological com-
pounds capable of inhibiting deregulated cellular 
growth, a hallmark trait in variety of cancers.  
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